Page last updated: 2024-11-05

fuberidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fuberidazole: fumigant; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fuberidazole : A ring assembly consisting of benzimidazole substituted at position 2 by a 2-furyl group. A fungicide used as a seed treatment to control Fusarium spp. in cereals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19756
CHEMBL ID201094
CHEBI ID81926
SCHEMBL ID23174
MeSH IDM0045182

Synonyms (64)

Synonym
101575-84-2
BB 0219597
2-furan-2-yl-1h-benzoimidazole
2-(2-furyl)-1h-benzimidazole
AE-641/02605022
2-(2-furyl)benzimidazole
fuberisazol
bayer 33172
fuberidazole
w vii/117
fuberidazol
fubridazole
nsc72670
bay 33172
1h-benzimidazole, 2-(2-furanyl)-
furidazol
voronit
nsc-72670
wln: t56 bm dnj c- bt5oj
voronite
benzimidazole, 2-(2-furyl)-
furidazole
3878-19-1
fuberidatol
b-33172
fuberidazole [bsi:iso]
nsc 72670
2-(2-furanyl)-1h-benzimidazole
einecs 223-404-0
fuberidazole, analytical standard
2-(furan-2-yl)-1h-benzimidazole
AKOS000591107
chebi:81926 ,
CHEMBL201094 ,
2-(furan-2-yl)-1h-benzo[d]imidazole
bdbm50180740
STK741597
C18737
unii-rxd450f6c7
rxd450f6c7 ,
tox21_301574
cas-3878-19-1
dtxsid4041995 ,
dtxcid2021995
NCGC00255946-01
2-benzimidazol-2-ylfuran
2-(furan-2-yl)-1h-1,3-benzodiazole
F0346-3053
fuberidazole [iso]
SCHEMBL23174
2-(furan-2-yl)-benzimidazole
2-(2'-furyl)-benzimidazole
2-(2-furyl)-1h-benzimidazole #
sr-01000393557
SR-01000393557-1
mfcd00055496
2-(fur-2-yl)-1h-benzimidazole
fuberidazole, pestanal(r), analytical standard
fuberidazole 10 microg/ml in methanol
Q5506905
furidazole; nsc 72670;voronit;bay 33172
LS-05915
CS-0013912
2-(2-furyl)-1h-1,3-benzimidazole

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antifungal agrochemicalAny substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
furansCompounds containing at least one furan ring.
benzimidazole fungicideCompounds that contain a benzimidazole moiety as a key feature of their structure and which have been used as fungicides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency28.25760.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.34570.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency21.90790.000221.22318,912.5098AID1259247; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.35530.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.62650.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency4.52290.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency17.59210.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency3.43760.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.30130.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743075; AID743077; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency24.27040.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency2.73060.001723.839378.1014AID743083
histone deacetylase 9 isoform 3Homo sapiens (human)Potency0.98990.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency4.85580.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.85580.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency29.35640.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency24.33650.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Methionine aminopeptidaseEscherichia coli K-12IC50 (µMol)10.00000.47203.50775.0000AID259066
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)207.00000.00000.54509.1000AID1059696
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00051.33138.0000AID259066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
proteolysisMethionine aminopeptidaseEscherichia coli K-12
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
initiator methionyl aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
ferrous iron bindingMethionine aminopeptidaseEscherichia coli K-12
metalloexopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
metal ion bindingMethionine aminopeptidaseEscherichia coli K-12
metalloaminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cytosolMethionine aminopeptidaseEscherichia coli K-12
cytosolMethionine aminopeptidaseEscherichia coli K-12
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID489475Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1507357Inhibition of VEGFR2 protein expression in human MCF7 cells at cytotoxic IC50 after 24 hrs by ELISA relative to untreated control2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
AID489473Inhibition of human MetAP1 at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1507354Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
AID1177821Inhibition of VEGF production in human MCF7 cells at cytotoxic IC50 level after 24 hrs by ELISA2014European journal of medicinal chemistry, Nov-24, Volume: 87Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.
AID1059694Binding affinity to soluble epoxide hydrolase (unknown origin) at 400 uM by STD-NMR assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Exploring the chemical space of multitarget ligands using aligned self-organizing maps.
AID1177820Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.
AID259067Inhibition of Mn2+ loaded MetAP expressed in Escherichia coli at upto 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID489469Inhibition of Escherichia coli MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1507355Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
AID489471Inhibition of Staphylococcus aureus MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID1059696Inhibition of recombinant soluble epoxide hydrolase (unknown origin) using PHOME as substrate incubated 15 mins prior to substrate addition measured for 30 minutes by fluorescence assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Exploring the chemical space of multitarget ligands using aligned self-organizing maps.
AID259068Inhibition of Co2+ loaded MetAP expressed in Escherichia coli at 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID259066Inhibition of Co2+ loaded MetAP expressed in Escherichia coli2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.26)18.7374
1990's0 (0.00)18.2507
2000's7 (36.84)29.6817
2010's9 (47.37)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.81 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]